Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 112.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 146,609 shares of the company's stock after purchasing an additional 77,611 shares during the period. Victory Capital Management Inc. owned 0.26% of Harmony Biosciences worth $5,045,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Pacer Advisors Inc. lifted its holdings in Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after acquiring an additional 351,582 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company's stock valued at $26,416,000 after acquiring an additional 140,690 shares during the last quarter. HealthInvest Partners AB lifted its holdings in Harmony Biosciences by 335.2% in the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company's stock valued at $6,075,000 after acquiring an additional 116,975 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Harmony Biosciences by 27.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,028 shares of the company's stock valued at $16,242,000 after acquiring an additional 100,586 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Harmony Biosciences by 68.4% in the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock valued at $9,217,000 after purchasing an additional 93,622 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Harmony Biosciences Stock Up 1.3 %

Shares of Harmony Biosciences stock traded up $0.46 during trading hours on Tuesday, reaching $34.78. 826,786 shares of the company were exchanged, compared to its average volume of 515,588. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The stock's fifty day moving average is $36.39 and its 200 day moving average is $35.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm has a market cap of $1.99 billion, a PE ratio of 16.48, a PEG ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.74 by $0.11. The firm had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.45 earnings per share. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Activity at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jeffrey Dierks sold 10,507 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock valued at $2,831,679 over the last quarter. 30.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HC Wainwright cut their target price on Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price on the stock. Mizuho boosted their target price on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, February 25th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $53.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.